郑州做近视激光手术可以用医保么(郑州矫正视力多少钱啊?) (今日更新中)

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Erwinaze to treat patients with acute lymphoblastic leukemia (ALL), who have developed an allergy to E. coli derived asparaginase and pegapargase chemotherapy drugs used to treat ALL.Acute lymphoblastic leukemia is a type of cancer in which the bone marrow makes too many lymphocytes, a type of white blood cell. White blood cells help the body fight infection and are formed in the bone marrow.Erwinaze is injected directly into the muscle three times a week and works by breaking down one of the body's protein building blocks (the amino acid, asparagine) that is present in the blood, and is necessary for the growth of all cells. Leukemia cells cannot produce this protein building block. When a patient is treated with Erwinaze the leukemia cells die. Normal human cells are able to make enough asparagine for their own needs through biosynthesis and will not be affected by treatment with Erwinaze."The approval of Erwinaze underscores the FDA's commitment to the approval of drugs for conditions with limited patient populations with unmet medical needs using novel trial endpoints," said Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.Side effects associated with Erwinaze treatment include serious allergic reactions, inflammation of the pancreas, high blood levels of liver enzymes, blood clotting, bleeding, nausea, vomiting and high blood sugar.

BEIJING, Oct. 13 (Xinhuanet) -- A new study finds that ginger may decrease the risk of colon cancer through diminishing the inflammation in the gut, according to media reports Thursday.Prior researches have found that chronicle inflammation in the gut is related to colon cancer, suggesting easing inflammation in intestines might reduce the risk of the cancer, said Suzanna M. Zick, lead author of the study published online in Cancer Prevention Research. Zick, also a naturopathic physician and research associate professor at University of Michigan Medical Center, and her colleagues, assigned 30 volunteers to take pills containing two grams of either placebo powder or ginger root extract, equivalent to about two tablespoons of ground-up raw ginger root.And they recorded the inflammations in the participants' intestines before and after the test period.The researchers found that participants taking ginger pills had 28 percent less inflammation in their intestines after the test. But no difference was found in those who took placebo.The findings are promising, but the researchers are not yet recommending people start taking more ginger at meal times. The study only involved 30 participants, so it is just a preliminary study. Zick said they hope to launch a larger study in the future, according to USA Today.

BEIJING, Dec. 10 (Xinhua) -- Pharmaceutical producers will risk having their operation license revoked if they use prohibited chemicals as medicine ingredients or involved in fake drug production, China's drug regulator said in a circular Saturday.The State Food and Drug Administration said it would name and shame pharmaceutical companies if they make phoney medicine and withdraw the operation licenses of pharmacies if they intentionally sell unqualified drugs.The circular came in the wake of several counterfeit medicine scandals uncovered by Chinese police in the past few months.On Nov. 4, police seized more than 65 million imitation medicinal tablets and arrested 114 suspects in a cross-provincial raid on counterfeit drugs.In October, police raided on an illegal drug production and sale network and ended up with the seizure of 190 million yuan (29.9 million U.S. dollars) worth of counterfeit drugs.The suspects were found to have used starch or corn powder as ingredients for bogus medicine, or re-packaged expired pharmaceuticals.Police also found animal feed and chemical pigments in the counterfeit products.

NANCHANG, Oct. 1 (Xinhua) -- A copper sword dating back more than 2,200 years has been discovered in east China's Jiangxi Province, local archaeologists said.The design and shape of the sword indicate that it was forged during the Warring States Period (475 BC - 221 BC), according to Li Guoli, curator of the Nanchang Museum, where the sword is currently being stored.Despite having little aesthetic or scientific value due to a lack of decor or inscriptions, the sword still offers insights into the type of military equipment used during the period, Li said.The identity of the sword's original owner and the precise location where the sword was forged and used are still unknown, Li said.The sword was discovered by a laborer surnamed Xiong in Jiangxi's capital of Nanchang. Xiong found the sword while sorting and cleaning stones that had been dredged up from a riverbank.An argument between Xiong and another worker who was trying to claim the sword aroused attention from the local law enforcement, who then convinced Xiong to turn the sword over to archaeological authorities.

BEIJING, Oct. 6 (Xinhua) -- China's first space lab module were in good condition and all tests went on "smoothly" during the past week, according to a statement issued by the country's space project authorities Thursday.The unmanned module, Tiangong-1, or Heavenly Palace-1, blasted off on Sept. 29 from Jiuquan Satellite Launch Center in northwest China's desert area.Tiangong-1 switched to the orbit of 362 kilometers high and had orbited the Earth for 109 times by 6:00 p.m. Thursday, the statement said.Tests on the module's remote control system, video/audio equipments, temperature/humidity sensors, docking facilities and other functions had been conducted successfully, it added.It also revealed that the Jiuquan Launch Center and other units were preparing for the launch of the Shenzhou-8 unmanned spacecraft, which is scheduled to join the Tiangong-1 later this year.Shenzhou-8 and Tiangong-1 are expected to perform China's first space docking at a height of 340 kilometers above the earth's surface.

来源：资阳报